Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory

Statement From the HF Collaboratory

Ankeet S. Bhatt, MD, MBA; William T. Abraham, MD; JoAnn Lindenfeld, MD; Michael Bristow, MD; Peter E. Carson, MD; G. Michael Felker, MD, MHS; Gregg C. Fonarow, MD; Stephen J. Greene, MD; Mitchell A. Psotka, MD, PHD; Scott D. Solomon, MD; Norman Stockbridge, MD, PHD; John R. Teerlink, MD; Muthiah Vaduganathan, MD, MPH; Janet Wittes, PHD; Mona Fiuzat, PHARMD; Christopher M. O'Connor, MD; Javed Butler, MD, MPH, MBA


JACC Heart Fail. 2021;9(1):1-12. 

In This Article


Choosing HF therapies and their dosages, with growing therapeutic options at multiple doses administered in various settings, is a complex process. With the potential of an influx of multiple new therapies, this complexity is expected to increase. Many approaches may be used to better understand and individualize the use of these therapies, although they should be pursued in a structured implementation science framework. For now, at least modulating 5 disease-modifying pathways with 4 therapies remains a core approach. Implementation science should be prioritized in tandem with discovery science to rapidly translate the scientific discoveries into clinical practice in ways that best serve patients with HF. Such an approach, if conceived in a manner that is thoughtful, deliberate, and collaborative, will improve longevity and quality of life for patients with HF and will help clinicians serve them better.